Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose
NCT ID: NCT06955234
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
90 participants
INTERVENTIONAL
2026-06-15
2026-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of an Intermittent Fasting and Dietary Supplement Regimen on Glycemic Variability
NCT05493553
Pharmacological Profile of Different Berberine Formulations, and Effects on Blood Sugar Levels
NCT05370261
The Effect of Oral Iron Supplements on Insulin and Glucose Metabolism in Overweight and Obese Women
NCT07315282
Effect of Dietary Glycemic Index on Beta-cell Function
NCT01386645
Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss
NCT01780870
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Berbevis 500 mg/die
Berbevis™, 250 mg x 2/day, 1 tablet in the morning and 1 in the evening.
Berbevis supplement
This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
Berbevis 750 mg/die
Berbevis™, 250 mg x 3/day, 2 tablets in the morning and 1 in the evening.
Berbevis supplement
This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
Berbevis 1000 mg/die
Berbevis™, 250 mg x 4/day, 2 tablets in the morning and 2 in the evening.
Berbevis supplement
This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Berbevis supplement
This intervention consists of a standardized oral dietary supplement containing Berberis aristata extract formulated in phospholipids (Berbevis™). The supplement is formulated to support metabolic balance. It is administered twice daily for 8 weeks to evaluate safety, tolerability, and dose-response effects in healthy adult volunteers.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 25 and 35 kg/m\^2
Exclusion Criteria
* BMI \< 25 or \> 35 kg/m\^2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda di Servizi alla Persona di Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1508/29032024
Identifier Type: OTHER
Identifier Source: secondary_id
1508/29032024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.